These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 18501589

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
    Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M, Allavena P.
    Cancer Res; 2010 Mar 15; 70(6):2235-44. PubMed ID: 20215499
    [Abstract] [Full Text] [Related]

  • 23. New drugs from the sea.
    D'Incalci M, Simone M, Tavecchio M, Damia G, Garbi A, Erba E.
    J Chemother; 2004 Nov 15; 16 Suppl 4():86-9. PubMed ID: 15688619
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
    Soares DG, Escargueil AE, Poindessous V, Sarasin A, de Gramont A, Bonatto D, Henriques JA, Larsen AK.
    Proc Natl Acad Sci U S A; 2007 Aug 07; 104(32):13062-7. PubMed ID: 17656556
    [Abstract] [Full Text] [Related]

  • 26. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
    Izbicka E, Lawrence R, Raymond E, Eckhardt G, Faircloth G, Jimeno J, Clark G, Von Hoff DD.
    Ann Oncol; 1998 Sep 07; 9(9):981-7. PubMed ID: 9818072
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.
    Tavecchio M, Natoli C, Ubezio P, Erba E, D'Incalci M.
    Cell Prolif; 2007 Dec 07; 40(6):885-904. PubMed ID: 18021177
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: new molecular insight into the mechanism of action.
    Martínez-Serra J, Maffiotte E, Martín J, Bex T, Navarro-Palou M, Ros T, Plazas JM, Vögler O, Gutiérrez A, Amat JC, Ramos R, Saus C, Ginés J, Alemany R, Diaz M, Besalduch J.
    Eur J Pharmacol; 2011 May 11; 658(2-3):57-64. PubMed ID: 21371453
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.
    Beumer JH, Rademaker-Lakhai JM, Rosing H, Lopez-Lazaro L, Beijnen JH, Schellens JH.
    Invest New Drugs; 2005 Oct 11; 23(5):429-36. PubMed ID: 16133794
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Preclinical and clinical results with the natural marine product ET-743.
    D'Incalci M, Jimeno J.
    Expert Opin Investig Drugs; 2003 Nov 11; 12(11):1843-53. PubMed ID: 14585059
    [Abstract] [Full Text] [Related]

  • 39. Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.
    Roylance R, Seddon B, McTiernan A, Sykes K, Daniels S, Whelan J.
    Clin Oncol (R Coll Radiol); 2007 Oct 11; 19(8):572-6. PubMed ID: 17624747
    [Abstract] [Full Text] [Related]

  • 40. The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro.
    Pauwels B, Korst AE, Lambrechts HA, Pattyn GG, de Pooter CM, Lardon F, Vermorken JB.
    Cancer Chemother Pharmacol; 2006 Aug 11; 58(2):219-28. PubMed ID: 16331496
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.